Oncology (Williston Park, N.Y.) (ONCOLOGY-NY )
- Impact factor3.19Show impact factor historyHide impact factor history
- 5-year impact2.52
- Cited half-life7.90
- Immediacy index0.49
- Article influence0.79
- WebsiteOncology website
- Other titlesOncology (Williston Park, N.Y.: Online)
- Material typeDocument, Periodical, Internet resource
- Document typeInternet Resource, Computer File, Journal / Magazine / Newspaper
Publications in this journal
Article: Cryoglobulinemic disease.[show abstract] [hide abstract]
ABSTRACT: "Cryoglobulinemia" refers to the presence of cryoglobulins (immunoglobulins that precipitate at variable temperatures < 37 degrees C [98.6 degrees F]) in serum. Monoclonal cryoglobulinemia (type I) involves a single type of monoclonal immunoglobulin, while mixed cryoglobulinemia involves a mixture either of polyclonal immunoglobulin (Ig) G and monoclonal IgM (type II), or of polyclonal IgG and polyclonal IgM (type Ill); both monoclonal and polyclonal IgM have rheumatoid factor activity. Cryoglobulinemia is a unique model of human disease for several reasons: (1) cryoglobulins are detected using a simple technical approach that is based on in vitro laboratory observation of cold precipitation in serum; (2) cryoglobulinemic organ damage may be produced by two different etiopathogenic mechanisms (accumulation of cryoglobulins and autoimmune-mediated vasculitic damage); and (3) cryoglobulinemia is associated with a wide range of etiologies, symptoms, and outcomes, and is considered a disease that combines elements of autoimmune and lymphoproliferative diseases. There are three main broad treatment strategies in cryoglobulinemia-conventional immunosuppression, antiviral treatment, and biologic therapy. Some agents, such as corticosteroids and rituximab, have been successfully used in all types of cryoglobulinemia; however, treatment should be modulated according to the underlying associated disease (chronic viral infections, autoimmune diseases, or cancer), the predominant etiopathogenic damage (vasculitis vs. hyperviscosity), and the severity of internal organ involvement.Oncology (Williston Park, N.Y.) 11/2013; 27(11):1098-1105, 1110-6.
Article: To transplant or not to transplant?Oncology (Williston Park, N.Y.) 11/2013; 27(11):1176, 1178.
- Oncology (Williston Park, N.Y.) 11/2013; 27(11):1125-6, 1128.
- Oncology (Williston Park, N.Y.) 11/2013; 27(11):1078, 1083-4, 1086.
- Oncology (Williston Park, N.Y.) 11/2013; 27(11):1051.
- Oncology (Williston Park, N.Y.) 11/2013; 27(11):1095-6, 1128.
- Oncology (Williston Park, N.Y.) 11/2013; 27(11):1068, 1070, 1072.
- [show abstract] [hide abstract]
ABSTRACT: Although metastatic colorectal cancer is typically incurable, in a good percentage of patients (20% to 50%) who have oligometastatic disease confined to a single organ-usually the liver-complete metastasectomy can result in cure. However, once the decision to pursue surgery is made, there remain a number of issues that must be addressed in order to ensure the best possible outcome. These include whether to perform synchronous or staged resections of the liver metastasis and the primary colon cancer; whether surgery should be performed before, after, or in the absence of chemotherapy; if chemotherapy is used, which agents will be best; and in patients with locally advanced rectal cancer, whether pelvic radiation should be incorporated into the treatment plan. Unfortunately, there are limited data that can provide guidance in deciding these questions in a particular patient. Here we present the insights we have arrived at through our own considerable experience with this patient population, and we reflect on the relevant studies that are available.Oncology (Williston Park, N.Y.) 11/2013; 27(11):1074-8.
- Oncology (Williston Park, N.Y.) 11/2013; 27(11):1137, 1143.
- Oncology (Williston Park, N.Y.) 11/2013; 27(11):1116, 1118.
- Oncology (Williston Park, N.Y.) 11/2013; 27(11):1160-1.
- Oncology (Williston Park, N.Y.) 11/2013; 27(11):1162-3, C3.
- [show abstract] [hide abstract]
ABSTRACT: Ten years ago, the clinician treating metastatic castration-resistant prostate cancer (CRPC) had palliative options for treatment of symptomatic patients, such as the combination of mitoxantrone combined with prednisone, as well as isotope therapy. In 2004, docetaxel-based chemotherapy regimens were shown to provide an overall survival benefit for patients with CRPC. Today, the prostate cancer oncologist is in the enviable position of having six U.S. Food and Drug Administration-approved agents to choose from: immunotherapy (sipuleucel-T), hormonal therapies (abiraterone, enzalutamide), radiopharmaceuticals (radium-223), and chemotherapy (docetaxel, cabazitaxel), in addition to agents being administered in clinical trials. In general, the sequencing of these drugs is based upon the entry criteria from the phase III trials that led to their approval. Selection of treatment is based on symptoms, sites of disease (bone vs visceral) and types of prior treatment (docetaxel-ineligible vs. pre-docetaxel vs post-docetaxel setting). Unfortunately, there is a lack of useful correlative biomarkers in prostate cancer to help oncologists select treatment. This problem is best illustrated in the post-docetaxel castration-resistant setting, for which there are indications to use all five other approved agents. In this review we will outline an approach to sequencing these new therapies, with particular attention paid to the biology of CRPC.Oncology (Williston Park, N.Y.) 11/2013; 27(11):1144-9, 1154-8.
- [show abstract] [hide abstract]
ABSTRACT: Due to its rarity, treatment guidelines for vaginal cancer are extrapolated from institutional reports and prospective studies of cervical and anal cancer. An expert panel was convened to reach consensus on the selection of imaging and therapeutic modalities. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) used by the panel to rate the appropriateness of imaging and treatment procedures. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. Four variants were developed to represent clinical scenarios in vaginal cancer management. Group members reached consensus on the appropriateness of the pretreatment evaluation and therapeutic interventions. This article represents the consensus opinion of an expert panel and may be used to inform clinical recommendations in vaginal cancer management.Oncology (Williston Park, N.Y.) 11/2013; 27(11):1166-73.
- Oncology (Williston Park, N.Y.) 11/2013; 27(11):1136, 1143.
- Oncology (Williston Park, N.Y.) 11/2013; 27(11):1088-90.
- Oncology (Williston Park, N.Y.) 11/2013; 27(11):1158-60.
- Oncology (Williston Park, N.Y.) 10/2013; 27(10):999-1000.
Article: PSA screening: the case in favor.Oncology (Williston Park, N.Y.) 10/2013; 27(10):980, 982.
- Oncology (Williston Park, N.Y.) 10/2013; 27(10):968, 970-1.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.
American Psychological Association,...
ISSN: 1939-2222, Impact factor: 3.99
ISSN: 1934-8800, Impact factor: 1.34
ISSN: 1898-4002, Impact factor: 0.8
ISSN: 1879-0534, Impact factor: 1.27
ISSN: 1873-0183, Impact factor: 6.37
ISSN: 1865-3774, Impact factor: 1.17